Skip to main content
. 2024 Dec 6;28(3):111536. doi: 10.1016/j.isci.2024.111536

Figure 3.

Figure 3

FAK inhibitor IN10018 effectively eradicates CAFs derived from normal fibroblasts

(A) The IF staining figures for NIH/3T3, NIH/3T3 co-cultured with CT26 cells, and NIH/3T3 co-cultured with NCI-N87 cells. The indicated cells were treated with PBS and 3 μm of IN10018 for 5 days. Phospho FAK Y397, FAP, and DAPI signals were recorded by IF staining.

(B–C) Western blot results for the IN10018-treated NIH/3T3 co-cultured with CT26 (B) or NCI-N87 (C) cells. The cells were treated with PBS and 3 μm of IN10018 for 3 or 5 days. The protein of NIH/3T3 was harvested for western blot to check the expression of the targets.

(D) Clonogenic assay for IN10018-treated NIH/3T3 co-cultured with CT26 cells or NCI-N87 cells. The cells were treated with PBS and 3 μm of IN10018 for 10 days and then the NIH/3T3 cell colonies were stained with crystal violet.

(E) The data analysis of colony assay from (D) by ImageJ. Data represent mean ± SEM. The unpaired student’s t test was used for the statistical analysis. NS, non-significant; ∗∗p < 0.01. Scale bar: 40 μm.